Recent chatter on X about ProMIS Neurosciences (PMN) has centered around the company’s progress in neurodegenerative disease therapies, particularly its Alzheimer’s candidate, PMN310, which has sparked significant interest following a Fast Track designation from regulatory authorities. Many users on the platform are expressing optimism about the potential market demand for such treatments, with some pointing to the stock’s dramatic surge earlier this year as a sign of investor confidence. The extension of a Nasdaq compliance deadline has also been noted as a positive development, giving the company more time to meet listing requirements.
However, not all discussions are uniformly positive, as some voices on X have raised concerns about the stock’s volatility and the challenges of breaking through key resistance levels to sustain an upward trend. There’s a mix of cautious hope and speculation about whether upcoming clinical updates or partnerships could drive further momentum. This blend of excitement and uncertainty keeps the conversation around PMN dynamic and closely watched by investors.
Note: This discussion summary was generated from an AI condensation of post data.
ProMIS Neurosciences Insider Trading Activity
ProMIS Neurosciences insiders have traded $PMN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PMN stock by insiders over the last 6 months:
- MAX A. MILBURY purchased 30,392 shares for an estimated $14,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ProMIS Neurosciences Hedge Fund Activity
We have seen 7 institutional investors add shares of ProMIS Neurosciences stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 196,930 shares (-8.4%) from their portfolio in Q2 2025, for an estimated $95,274
- ALLY BRIDGE GROUP (NY) LLC removed 150,271 shares (-10.1%) from their portfolio in Q2 2025, for an estimated $72,701
- ALLOSTERY INVESTMENTS LP removed 77,983 shares (-33.4%) from their portfolio in Q2 2025, for an estimated $37,728
- CITADEL ADVISORS LLC added 63,429 shares (+inf%) to their portfolio in Q2 2025, for an estimated $30,686
- GRAYPOINT LLC added 52,833 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,560
- KINGSVIEW WEALTH MANAGEMENT, LLC added 31,062 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,027
- SPHERA FUNDS MANAGEMENT LTD. removed 30,000 shares (-1.6%) from their portfolio in Q2 2025, for an estimated $14,514
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ProMIS Neurosciences Analyst Ratings
Wall Street analysts have issued reports on $PMN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/14/2025
- Maxim Group issued a "Buy" rating on 05/12/2025
To track analyst ratings and price targets for ProMIS Neurosciences, check out Quiver Quantitative's $PMN forecast page.
ProMIS Neurosciences Price Targets
Multiple analysts have issued price targets for $PMN recently. We have seen 2 analysts offer price targets for $PMN in the last 6 months, with a median target of $3.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $4.0 on 07/14/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 05/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
